Metabolism/Glycosylation Inhibitor

WP1122 is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, which, based on pre-clinical testing, enables increased cellular uptake, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater uptake in the brain. Our approach was inspired by the same principle that distinguishes morphine from heroin. Heroin is chemically the diacetyl ester of morphine. While morphine has a limited ability to cross the blood brain barrier (making it a good candidate for pain killing without impairing mental function), its diacetyl form, heroin, has the ability to accumulate in the brain by 10 to 100-fold more than morphine. Once across the blood brain barrier, the acetyl groups shown in this chemical diagram are cleaved off by natural enzyme esterases, leaving pure morphine to accumulate in the brain.

Ongoing COVID-19 Clinical Study:

Phase 1a


Key Highlights:

Prodrug of glucose decoy enables drug-like properties

Targets glycolysis and glycosylation limits viral infectivity and replication

Additional Applications in Oncology:

Glioblastoma (GBM) Brain Tumors

Pancreatic Cancer


Our Clinical Studies

Sign Up For Alerts